Mitochondrial genome alterations in cancer: From mutations and epigenetics to targeted therapies.
Mitochondrial DNA changes in cancer reveal new drug targets and resistance mechanisms beyond traditional nuclear genetics.
This BBRC review synthesizes knowledge on mitochondrial genome alterations in cancer—somatic mtDNA mutations, epigenetic changes, and copy number variations—and their implications for tumor metabolism, drug resistance, and targeted therapy development. The review highlights emerging mitochondria-directed therapeutic strategies with relevance to precision oncology across multiple cancer types.
What the study was
- Study design
- Comprehensive narrative review
- Population
- Cancer patients with mitochondrial genome alterations across cancer types
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochemical and biophysical research communications
Why it surfaced
BBRC review; mitochondrial genome alterations as precision oncology targets; review synthesis useful for pipeline context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.